OBJECTIVE: There are several known monogenic causes of high and low high-density lipoprotein cholesterol (HDL-C) levels, but traditional sequencing studies have had limited success in identifying mutations in the majority of individuals with extreme HDL-C levels. The aim of this study was to assess the power of a targeted high-throughput sequencing strategy to elucidate the genetic basis of extreme HDL-C phenotypes. APPROACH AND RESULTS: We sequenced 195 genes with either established or implicated roles in lipid and lipoprotein metabolism plus 78 lipid-unrelated genes in patients with HDL-C <1st (n=40) or >99th (n=40) percentile values, and the results were compared with those of 498 individuals representative of the Dutch general population and 95 subjects with normal HDL-C (between 40th and 60th percentile values). The extreme HDL cohort carried more rare nonsynonymous variants in the lipid geneset than both the general population (odds ratio, 1.39; P=0.019) and normal HDL-C (odds ratio, 1.43; P=0.040) cohorts. The prevalence of such variants in the lipid-related and lipid-unrelated genesets was similar in the control groups, indicative of equal mutation rates. In the extreme HDL cohort, however, there was enrichment of rare nonsynonymous variants in the lipid versus the control geneset (odds ratio, 2.23; P<0.0001), and 70% of the lipid-related variants altered conserved nucleotides. The lipid geneset comprised 4 nonsense, 10 splice-site, and 8 coding indel variants, whereas the control geneset contained only 1 such variant. In the lipid geneset, 87% and 28% of the patients carried ≥ 2 and ≥ 5 rare variants. CONCLUSIONS: This study suggests that most extreme HDL-C phenotypes have a polygenic origin.
OBJECTIVE: There are several known monogenic causes of high and low high-density lipoprotein cholesterol (HDL-C) levels, but traditional sequencing studies have had limited success in identifying mutations in the majority of individuals with extreme HDL-C levels. The aim of this study was to assess the power of a targeted high-throughput sequencing strategy to elucidate the genetic basis of extreme HDL-C phenotypes. APPROACH AND RESULTS: We sequenced 195 genes with either established or implicated roles in lipid and lipoprotein metabolism plus 78 lipid-unrelated genes in patients with HDL-C <1st (n=40) or >99th (n=40) percentile values, and the results were compared with those of 498 individuals representative of the Dutch general population and 95 subjects with normal HDL-C (between 40th and 60th percentile values). The extreme HDL cohort carried more rare nonsynonymous variants in the lipid geneset than both the general population (odds ratio, 1.39; P=0.019) and normal HDL-C (odds ratio, 1.43; P=0.040) cohorts. The prevalence of such variants in the lipid-related and lipid-unrelated genesets was similar in the control groups, indicative of equal mutation rates. In the extreme HDL cohort, however, there was enrichment of rare nonsynonymous variants in the lipid versus the control geneset (odds ratio, 2.23; P<0.0001), and 70% of the lipid-related variants altered conserved nucleotides. The lipid geneset comprised 4 nonsense, 10 splice-site, and 8 coding indel variants, whereas the control geneset contained only 1 such variant. In the lipid geneset, 87% and 28% of the patients carried ≥ 2 and ≥ 5 rare variants. CONCLUSIONS: This study suggests that most extreme HDL-C phenotypes have a polygenic origin.
Authors: Singh N Sadananda; Jia Nee Foo; Meng Tiak Toh; Lubomira Cermakova; Laia Trigueros-Motos; Teddy Chan; Herty Liany; Jennifer A Collins; Sima Gerami; Roshni R Singaraja; Michael R Hayden; Gordon A Francis; Jiri Frohlich; Chiea Chuen Khor; Liam R Brunham Journal: J Lipid Res Date: 2015-08-08 Impact factor: 5.922
Authors: Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Alessandra N Bazzano; Somesh Nigam; Gang Hu Journal: Stroke Date: 2019-02 Impact factor: 7.914
Authors: Nathan O Stitziel; Gina M Peloso; Marianne Abifadel; Angelo B Cefalu; Sigrid Fouchier; M Mahdi Motazacker; Hayato Tada; Daniel B Larach; Zuhier Awan; Jorge F Haller; Clive R Pullinger; Mathilde Varret; Jean-Pierre Rabès; Davide Noto; Patrizia Tarugi; Masa-Aki Kawashiri; Atsushi Nohara; Masakazu Yamagishi; Marjorie Risman; Rahul Deo; Isabelle Ruel; Jay Shendure; Deborah A Nickerson; James G Wilson; Stephen S Rich; Namrata Gupta; Deborah N Farlow; Benjamin M Neale; Mark J Daly; John P Kane; Mason W Freeman; Jacques Genest; Daniel J Rader; Hiroshi Mabuchi; John J P Kastelein; G Kees Hovingh; Maurizio R Averna; Stacey Gabriel; Catherine Boileau; Sekar Kathiresan Journal: Circ Cardiovasc Genet Date: 2015-01-27
Authors: Roshni R Singaraja; Ian Tietjen; G Kees Hovingh; Patrick L Franchini; Chris Radomski; Kenny Wong; Margaret vanHeek; Ioannis M Stylianou; Linus Lin; Liangsu Wang; Lyndon Mitnaul; Brian Hubbard; Michael Winther; Maryanne Mattice; Annick Legendre; Robin Sherrington; John J Kastelein; Karen Akinsanya; Andrew Plump; Michael R Hayden Journal: J Lipid Res Date: 2014-06-02 Impact factor: 5.922
Authors: Jacqueline S Dron; Jian Wang; Cécile Low-Kam; Sumeet A Khetarpal; John F Robinson; Adam D McIntyre; Matthew R Ban; Henian Cao; David Rhainds; Marie-Pierre Dubé; Daniel J Rader; Guillaume Lettre; Jean-Claude Tardif; Robert A Hegele Journal: J Lipid Res Date: 2017-09-04 Impact factor: 5.922
Authors: Federico Oldoni; Julian C van Capelleveen; Nawar Dalila; Justina C Wolters; Joerg Heeren; Richard J Sinke; David Y Hui; Geesje M Dallinga-Thie; Ruth Frikke-Schmidt; Kees G Hovingh; Bart van de Sluis; Anne Tybjærg-Hansen; Jan Albert Kuivenhoven Journal: Arterioscler Thromb Vasc Biol Date: 2018-05-31 Impact factor: 8.311